FOXO4-DRI is a retro-inverso D-amino acid peptide that disrupts the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis selectively in senescent but not normal cells. The design exploits a key mechanism of senescent cell survival: FOXO4 sequesters p53 in the nucleus, preventing p53-mediated apoptosis — which would otherwise eliminate damaged senescent cells. By blocking this interaction, FOXO4-DRI releases p53 to execute apoptosis specifically in FOXO4-overexpressing senescent cells. The Baar et al. 2017 Nature paper established FOXO4-DRI as the founding senolytic peptide, demonstrating improved healthspan, physical fitness, and fur coat restoration in naturally aged and irradiation-induced senescence mouse models.
Senescent cells upregulate FOXO4 as a survival mechanism — FOXO4 binds nuclear p53, preventing p53-induced apoptosis (a core component of the senescence-associated apoptosis resistance, SAAR). FOXO4-DRI disrupts this interaction:
Selectivity: Normal cells express low FOXO4 → minimal p53 release → remain viable. Senescent cells express high FOXO4 → FOXO4-DRI has large effect.
What makes FOXO4-DRI different from small molecule senolytics
The two established small-molecule senolytics (navitoclax targeting BCL-2; dasatinib + quercetin) work through broad anti-apoptotic pathway inhibition — they have off-target effects on platelets (navitoclax) and multiple kinases (dasatinib). FOXO4-DRI disrupts a single protein-protein interaction (FOXO4-p53) that is specifically upregulated in senescent cells — making it the most mechanistically targeted senolytic available. This selectivity is the main research advantage: studying senolysis without broad BCL-2 or kinase inhibition as a confounder.
Key Research Studies & Clinical Data
Key senolytic peptide research
Study
Model
Key result
Baar et al. 2017 (Nature)
Naturally aged mice + irradiation model
FOXO4-DRI restored fur density, exercise tolerance, renal function — established proof-of-concept
Ogrodnik et al. 2019 (Nat Met)
Obesity-induced senescence mouse
Senescent cell clearance reduced adipose inflammation and improved metabolic parameters
Baker et al. 2016 (Nature)
INK-ATTAC transgenic senolysis model
Pharmacogenetic senolysis extended healthspan and delayed multimorbidity — sets context for FOXO4-DRI
Research Protocols — FOXO4-DRI
Protocol 1: Aged mouse senolytic protocol
FOXO4-DRI 5 mg/kg IP 3 consecutive days per month × 3 months in 24-month-old C57BL/6 mice. Senescent cell burden: p16INK4a and p21 mRNA (qPCR), SA-β-gal staining (skin punch/kidney), SASP cytokines (IL-6, IL-8, MCP-1, ELISA). Physical performance: rotarod, grip strength, treadmill endurance. Organ histology.
Protocol 2: Irradiation-induced senescence
Sub-lethal irradiation (6.5 Gy) in 4-month-old mice → 10-day recovery → FOXO4-DRI 5 mg/kg IP × 3 days. p16/p21, SA-β-gal, SASP, body weight, blood counts, renal function (BUN, creatinine).
Protocol 3: Selectivity assay (in vitro)
FOXO4-DRI at 1–10 µM in senescent (bleomycin 20 µg/mL 10 days) vs normal human fibroblasts. Viability (Annexin V/PI flow cytometry), caspase-3 activity (fluorometric), p53 nuclear translocation (IF), PUMA mRNA.
FOXO4-DRI is a retro-inverso D-amino acid senolytic peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 protein-protein interaction. It is the first and most mechanistically targeted senolytic peptide, described in the Baar et al. 2017 Nature paper.
What is a senolytic?
A senolytic is a compound that selectively eliminates senescent cells — cells that have permanently exited the cell cycle but remain metabolically active and secrete pro-inflammatory cytokines (the senescence-associated secretory phenotype, SASP). Senescent cell accumulation drives inflammation, tissue dysfunction, and multiple aspects of biological ageing.
How does FOXO4-DRI selectively kill senescent cells?
Senescent cells upregulate FOXO4, which sequesters p53 and prevents apoptosis. FOXO4-DRI disrupts the FOXO4-p53 interaction, releasing p53 to activate PUMA and mitochondrial apoptosis. Normal cells have low FOXO4 expression, so FOXO4-DRI has minimal effect on them.
What did the 2017 Nature paper show?
Baar et al. 2017 demonstrated that FOXO4-DRI cleared senescent cells in naturally aged mice and irradiation models, restoring physical fitness (grip strength, treadmill), fur coat density, and renal function — without apparent toxicity to normal cells.
What formats does QSC supply FOXO4-DRI in?
QSC supplies FOXO4-DRI as lyophilised research vials, ≥99% purity HPLC verified with Janoshik COA. Ships from domestic QSC warehouses in USA, EU, UK, Canada, and Australia.
Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use. Not approved by the FDA or equivalent regulatory bodies for human administration. All purchases confirm research intent and compliance with applicable local regulations.
